Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ro 24-7429
- Development stage
- Phase 1
- Lead developer
- Roche
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Ro 24-7429 is a small molecule benzodiazepine derivative developed as an orally active antagonist of the HIV transactivator protein Tat and as an inhibitor of runt-related transcription factor 1 (RUNX1). It was originally investigated for its anti-HIV activity but showed no significant antiviral effect in clinical trials. More recently, it has demonstrated antifibrotic and anti-inflammatory effects in preclinical models by inhibiting RUNX1-mediated pathways. The drug was initially developed by F. Hoffmann-La Roche for HIV infection and later explored for potential use in fibrotic diseases such as pulmonary fibrosis[1][4][5][10].
- Other names
- 7-chloro-N-methyl-5-(1H-pyrrol-2-yl)-3H-1,4-benzodiazepin-2-amineUNII-MLW2GKK8LIUNII-MLW-2GKK8LIUNII-MLW 2GKK8LI
02
Targets
HIV-1 Tat-dependent transactivation complexRUNX1Tat (HIV-1 Tat)
Beyond the preview
Go deeper on Ro 24-7429.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ro 24-7429.